Day One Biopharmaceuticals (DAWN) Competitors $12.54 +0.14 (+1.13%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DAWN vs. VKTX, AXSM, KRYS, TGTX, OGN, SRRK, ALVO, RARE, ADMA, and BHVNShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), TG Therapeutics (TGTX), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Viking Therapeutics Axsome Therapeutics Krystal Biotech TG Therapeutics Organon & Co. Scholar Rock Alvotech Ultragenyx Pharmaceutical ADMA Biologics Biohaven Day One Biopharmaceuticals (NASDAQ:DAWN) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the MarketBeat Community favor DAWN or VKTX? Viking Therapeutics received 574 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 67.14% of users gave Day One Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes4767.14% Underperform Votes2332.86% Viking TherapeuticsOutperform Votes62179.92% Underperform Votes15620.08% Which has better valuation & earnings, DAWN or VKTX? Viking Therapeutics is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One BiopharmaceuticalsN/AN/A-$188.92M-$1.03-12.17Viking TherapeuticsN/AN/A-$85.89M-$0.93-35.11 Do analysts rate DAWN or VKTX? Day One Biopharmaceuticals currently has a consensus price target of $35.86, indicating a potential upside of 185.94%. Viking Therapeutics has a consensus price target of $106.75, indicating a potential upside of 226.95%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Day One Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Viking Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.15 Is DAWN or VKTX more profitable? Viking Therapeutics' return on equity of -12.73% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% Viking Therapeutics N/A -12.73%-12.31% Does the media prefer DAWN or VKTX? In the previous week, Day One Biopharmaceuticals had 1 more articles in the media than Viking Therapeutics. MarketBeat recorded 9 mentions for Day One Biopharmaceuticals and 8 mentions for Viking Therapeutics. Day One Biopharmaceuticals' average media sentiment score of 0.41 beat Viking Therapeutics' score of 0.33 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in DAWN or VKTX? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, DAWN or VKTX? Day One Biopharmaceuticals has a beta of -1.46, indicating that its share price is 246% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. SummaryViking Therapeutics beats Day One Biopharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.26B$6.19B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-12.179.7689.3117.33Price / SalesN/A306.691,265.82136.54Price / CashN/A61.4443.7535.97Price / Book3.156.055.324.80Net Income-$188.92M$154.62M$122.60M$224.91M7 Day Performance6.27%-1.67%0.61%1.77%1 Month Performance-0.79%-2.34%1.50%2.22%1 Year Performance-9.20%0.93%27.22%20.66% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals1.7771 of 5 stars$12.54+1.1%$35.86+185.9%-9.2%$1.26BN/A-12.1760News CoverageVKTXViking Therapeutics3.9209 of 5 stars$38.88-1.1%$106.75+174.6%+52.4%$4.33BN/A-41.8120Analyst ForecastGap DownAXSMAxsome Therapeutics4.6334 of 5 stars$89.27+11.5%$129.43+45.0%+7.5%$4.33B$338.46M-13.67380Analyst RevisionGap UpKRYSKrystal Biotech4.8312 of 5 stars$150.31-1.7%$206.67+37.5%+17.8%$4.32B$241.52M84.92229Short Interest ↓TGTXTG Therapeutics4.4921 of 5 stars$27.67-4.2%$40.67+47.0%+93.1%$4.31B$264.79M-276.67290Analyst ForecastAnalyst RevisionNews CoverageOGNOrganon & Co.4.8105 of 5 stars$15.63-1.4%$21.33+36.5%-0.8%$4.03B$6.41B3.1010,000Positive NewsSRRKScholar Rock3.1277 of 5 stars$42.60+5.2%$40.43-5.1%+176.7%$3.99B$33.19M-18.13140Positive NewsALVOAlvotech2.552 of 5 stars$13.22-2.2%$18.00+36.2%+7.4%$3.99B$391.87M-7.151,026Positive NewsRAREUltragenyx Pharmaceutical4.599 of 5 stars$43.16+2.6%$92.29+113.8%-7.9%$3.99B$522.75M-6.671,276Analyst RevisionNews CoverageADMAADMA Biologics3.9377 of 5 stars$16.49-11.2%$21.25+28.9%+224.9%$3.90B$382.81M58.89530Short Interest ↑Analyst RevisionPositive NewsGap DownBHVNBiohaven2.6099 of 5 stars$37.44+2.0%$63.00+68.3%-13.6%$3.79B$462.51M-4.00239Short Interest ↑Gap Up Related Companies and Tools Related Companies Viking Therapeutics Competitors Axsome Therapeutics Competitors Krystal Biotech Competitors TG Therapeutics Competitors Organon & Co. Competitors Scholar Rock Competitors Alvotech Competitors Ultragenyx Pharmaceutical Competitors ADMA Biologics Competitors Biohaven Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DAWN) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
